

Peter M Siegel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5061722/publications.pdf>

Version: 2024-02-01

94
papers

14,166
citations

76031

42
h-index

49824

91
g-index

97
all docs

97
docs citations

97
times ranked

22961
citing authors

#	ARTICLE	IF	CITATIONS
1	Genes that mediate breast cancer metastasis to lung. <i>Nature</i> , 2005, 436, 518-524.	13.7	2,581
2	A multigenic program mediating breast cancer metastasis to bone. <i>Cancer Cell</i> , 2003, 3, 537-549.	7.7	2,325
3	Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. <i>Nature</i> , 2012, 482, 226-231.	13.7	2,129
4	AMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth In Vivo. <i>Cell Metabolism</i> , 2013, 17, 113-124.	7.2	754
5	PDK1-Dependent Metabolic Reprogramming Dictates Metastatic Potential in Breast Cancer. <i>Cell Metabolism</i> , 2015, 22, 577-589.	7.2	430
6	Transforming growth factor β signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 8430-8435.	3.3	409
7	Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. <i>EMBO Journal</i> , 1999, 18, 2149-2164.	3.5	389
8	Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. <i>Nature Genetics</i> , 2014, 46, 462-466.	9.4	381
9	Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. <i>Oncogene</i> , 2018, 37, 3183-3199.	2.6	317
10	Metabolic Plasticity as a Determinant of Tumor Growth and Metastasis. <i>Cancer Research</i> , 2016, 76, 5201-5208.	0.4	214
11	Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. <i>Molecular and Cellular Biology</i> , 1994, 14, 7068-7077.	1.1	188
12	PGC-1 α Promotes Breast Cancer Metastasis and Confers Bioenergetic Flexibility against Metabolic Drugs. <i>Cell Metabolism</i> , 2017, 26, 778-787.e5.	7.2	181
13	Glycoprotein Nonmetastatic B Is an Independent Prognostic Indicator of Recurrence and a Novel Therapeutic Target in Breast Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 2147-2156.	3.2	172
14	Fusion of TTYH1 with the C19MC microRNA cluster drives expression of a brain-specific DNMT3B isoform in the embryonal brain tumor ETMR. <i>Nature Genetics</i> , 2014, 46, 39-44.	9.4	167
15	ADAM10 Releases a Soluble Form of the GPNMB/Osteoactivin Extracellular Domain with Angiogenic Properties. <i>PLoS ONE</i> , 2010, 5, e12093.	1.1	149
16	Osteoactivin Promotes Breast Cancer Metastasis to Bone. <i>Molecular Cancer Research</i> , 2007, 5, 1001-1014.	1.5	146
17	Immature Low-Density Neutrophils Exhibit Metabolic Flexibility that Facilitates Breast Cancer Liver Metastasis. <i>Cell Reports</i> , 2019, 27, 3902-3915.e6.	2.9	144
18	The role of claudins in cancer metastasis. <i>Oncogene</i> , 2017, 36, 1176-1190.	2.6	140

#	ARTICLE	IF	CITATIONS
19	Claudin-2 is selectively enriched in and promotes the formation of breast cancer liver metastases through engagement of integrin complexes. <i>Oncogene</i> , 2011, 30, 1318-1328.	2.6	130
20	Novel Activating Mutations in the <i>neu</i> Proto-oncogene Involved in Induction of Mammary Tumors. <i>Molecular and Cellular Biology</i> , 1994, 14, 7068-7077.	1.1	124
21	Granulocytic immune infiltrates are essential for the efficient formation of breast cancer liver metastases. <i>Breast Cancer Research</i> , 2015, 17, 45.	2.2	103
22	Mammary tumors expressing the <i>neu</i> proto-oncogene possess elevated c-Src tyrosine kinase activity. <i>Molecular and Cellular Biology</i> , 1994, 14, 735-743.	1.1	96
23	Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer. <i>OncoTargets and Therapy</i> , 2013, 6, 839.	1.0	95
24	Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Locally Advanced or Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 3619-3625.	0.8	94
25	Mutations affecting conserved cysteine residues within the extracellular domain of Neu promote receptor dimerization and activation.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996, 93, 8878-8883.	3.3	91
26	Claudin-2 Promotes Breast Cancer Liver Metastasis by Facilitating Tumor Cell Interactions with Hepatocytes. <i>Molecular and Cellular Biology</i> , 2012, 32, 2979-2991.	1.1	89
27	Mad Upregulation and Id2 Repression Accompany Transforming Growth Factor (TGF)- β -mediated Epithelial Cell Growth Suppression. <i>Journal of Biological Chemistry</i> , 2003, 278, 35444-35450.	1.6	85
28	Exosomal Release of L-Plastin by Breast Cancer Cells Facilitates Metastatic Bone Osteolysis. <i>Translational Oncology</i> , 2019, 12, 462-474.	1.7	66
29	Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer. , 2017, 179, 127-141.		64
30	Emerging therapeutic targets in breast cancer bone metastasis. <i>Future Oncology</i> , 2010, 6, 55-74.	1.1	63
31	Signaling through ShcA Is Required for Transforming Growth Factor β 2- and Neu/ErbB-2-Induced Breast Cancer Cell Motility and Invasion. <i>Molecular and Cellular Biology</i> , 2008, 28, 3162-3176.	1.1	61
32	GPNMB cooperates with neuropilin-1 to promote mammary tumor growth and engages integrin α 5 β 1 for efficient breast cancer metastasis. <i>Oncogene</i> , 2015, 34, 5494-5504.	2.6	61
33	Translational and HIF-1 α -Dependent Metabolic Reprogramming Underpin Metabolic Plasticity and Responses to Kinase Inhibitors and Biguanides. <i>Cell Metabolism</i> , 2018, 28, 817-832.e8.	7.2	61
34	Metabolic Profiles Associated With Metformin Efficacy in Cancer. <i>Frontiers in Endocrinology</i> , 2018, 9, 372.	1.5	61
35	Creatine-mediated crosstalk between adipocytes and cancer cells regulates obesity-driven breast cancer. <i>Cell Metabolism</i> , 2021, 33, 499-512.e6.	7.2	61
36	LPP is a Src substrate required for invadopodia formation and efficient breast cancer lung metastasis. <i>Nature Communications</i> , 2017, 8, 15059.	5.8	59

#	ARTICLE	IF	CITATIONS
37	Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas. <i>Clinical Cancer Research</i> , 2018, 24, 6483-6494.	3.2	55
38	CCN3 Impairs Osteoblast and Stimulates Osteoclast Differentiation to Favor Breast Cancer Metastasis to Bone. <i>American Journal of Pathology</i> , 2011, 178, 2377-2388.	1.9	54
39	Chordin-Like 1 Suppresses Bone Morphogenetic Protein 4-Induced Breast Cancer Cell Migration and Invasion. <i>Molecular and Cellular Biology</i> , 2016, 36, 1509-1525.	1.1	53
40	Optimizing live-cell fluorescence imaging conditions to minimize phototoxicity. <i>Journal of Cell Science</i> , 2020, 133, .	1.2	51
41	Lyn modulates Claudin-2 expression and is a therapeutic target for breast cancer liver metastasis. <i>Oncotarget</i> , 2015, 6, 9476-9487.	0.8	47
42	LKB1 deficiency in T cells promotes the development of gastrointestinal polyposis. <i>Science</i> , 2018, 361, 406-411.	6.0	47
43	Decreased PCSK9 expression in human hepatocellular carcinoma. <i>BMC Gastroenterology</i> , 2015, 15, 176.	0.8	46
44	The influence of the pre-metastatic niche on breast cancer metastasis. <i>Cancer Letters</i> , 2016, 380, 281-288.	3.2	45
45	Afadin cooperates with Claudin-2 to promote breast cancer metastasis. <i>Genes and Development</i> , 2019, 33, 180-193.	2.7	45
46	LKB1 is a central regulator of tumor initiation and pro-growth metabolism in ErbB2-mediated breast cancer. <i>Cancer & Metabolism</i> , 2013, 1, 18.	2.4	44
47	MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB. <i>Clinical Cancer Research</i> , 2016, 22, 6088-6098.	3.2	43
48	Mammary gland neoplasia: insights from transgenic mouse models. <i>BioEssays</i> , 2000, 22, 554-563.	1.2	40
49	ABCC5 supports osteoclast formation and promotes breast cancer metastasis to bone. <i>Breast Cancer Research</i> , 2012, 14, R149.	2.2	40
50	Osteoclast precursors acquire sensitivity to breast cancer derived factors early in differentiation. <i>Bone</i> , 2008, 43, 386-393.	1.4	39
51	Transcription factor regulatory networks in mammary epithelial development and tumorigenesis. <i>Oncogene</i> , 2010, 29, 2753-2759.	2.6	39
52	Targeting tumor microenvironment in cancer therapy. <i>Cancer Letters</i> , 2016, 380, 203-204.	3.2	39
53	A complex containing LPP and β -Actinin mediates TGF β ² -induced migration and invasion of ErbB2-expressing breast cancer cells. <i>Journal of Cell Science</i> , 2013, 126, 1981-91.	1.2	37
54	The IGF-Trap: Novel Inhibitor of Carcinoma Growth and Metastasis. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 982-993.	1.9	34

#	ARTICLE	IF	CITATIONS
55	CCN3 modulates bone turnover and is a novel regulator of skeletal metastasis. <i>Journal of Cell Communication and Signaling</i> , 2012, 6, 73-85.	1.8	33
56	Peroxiredoxin 4: A novel secreted mediator of cancer induced osteoclastogenesis. <i>Cancer Letters</i> , 2015, 361, 262-270.	3.2	32
57	Claudin-2 promotes colorectal cancer liver metastasis and is a biomarker of the replacement type growth pattern. <i>Communications Biology</i> , 2021, 4, 657.	2.0	32
58	EPHB6 augments both development and drug sensitivity of triple-negative breast cancer tumours. <i>Oncogene</i> , 2018, 37, 4073-4093.	2.6	30
59	Histopathological growth patterns of liver metastasis: updated consensus guidelines for pattern scoring, perspectives and recent mechanistic insights. <i>British Journal of Cancer</i> , 2022, 127, 988-1013.	2.9	30
60	Chemogenomic profiling of breast cancer patient-derived xenografts reveals targetable vulnerabilities for difficult-to-treat tumors. <i>Communications Biology</i> , 2020, 3, 310.	2.0	28
61	5â€²-Inositol phosphatase SHIP2 recruits Mena to stabilize invadopodia for cancer cell invasion. <i>Journal of Cell Biology</i> , 2016, 214, 719-734.	2.3	27
62	Runt related transcription factor-1 plays a central role in vessel co-option of colorectal cancer liver metastases. <i>Communications Biology</i> , 2021, 4, 950.	2.0	26
63	Emerging roles for LPP in metastatic cancer progression. <i>Journal of Cell Communication and Signaling</i> , 2018, 12, 143-156.	1.8	25
64	STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancer. <i>Nature Communications</i> , 2021, 12, 3299.	5.8	24
65	Oncogenic Activating Mutations in the neu/erbB-2 Oncogene Are Involved in the Induction of Mammary Tumors. <i>Annals of the New York Academy of Sciences</i> , 1999, 889, 45-51.	1.8	23
66	A Three-Dimensional Dense Collagen Hydrogel to Model Cancer Cell/Osteoblast Interactions. <i>Journal of Functional Biomaterials</i> , 2018, 9, 72.	1.8	23
67	Integrin-uPAR signaling leads to FRA-1 phosphorylation and enhanced breast cancer invasion. <i>Breast Cancer Research</i> , 2018, 20, 9.	2.2	23
68	Resistance to different anthracycline chemotherapeutics elicits distinct and actionable primary metabolic dependencies in breast cancer. <i>ELife</i> , 2021, 10, .	2.8	23
69	The histone H3K9 demethylase KDM3A promotes anoikis by transcriptionally activating pro-apoptotic genes BNIP3 and BNIP3L. <i>ELife</i> , 2016, 5, .	2.8	23
70	GPNMB augments Wnt-1 mediated breast tumor initiation and growth by enhancing PI3K/AKT/mTOR pathway signaling and β^2 -catenin activity. <i>Oncogene</i> , 2019, 38, 5294-5307.	2.6	22
71	Neutrophils: Orchestrators of the Malignant Phenotype. <i>Frontiers in Immunology</i> , 2020, 11, 1778.	2.2	20
72	C3a elicits unique migratory responses in immature low-density neutrophils. <i>Oncogene</i> , 2020, 39, 2612-2623.	2.6	20

#	ARTICLE	IF	CITATIONS
73	Distinct Phosphotyrosine-dependent Functions of the ShcA Adaptor Protein Are Required for Transforming Growth Factor β^2 (TGF β^2)-induced Breast Cancer Cell Migration, Invasion, and Metastasis. <i>Journal of Biological Chemistry</i> , 2013, 288, 5210-5222.	1.6	19
74	CD109 acts as a gatekeeper of the epithelial trait by suppressing epithelial to mesenchymal transition in squamous cell carcinoma cells in vitro. <i>Scientific Reports</i> , 2019, 9, 16317.	1.6	19
75	Invasive growth associated with cold-inducible RNA-binding protein expression drives recurrence of surgically resected brain metastases. <i>Neuro-Oncology</i> , 2021, 23, 1470-1480.	0.6	18
76	High Throughput Traction Force Microscopy Using PDMS Reveals Dose-Dependent Effects of Transforming Growth Factor- β on the Epithelial-to-Mesenchymal Transition. <i>Journal of Visualized Experiments</i> , 2019, , .	0.2	15
77	Folliculin impairs breast tumor growth by repressing TFE3-dependent induction of the Warburg effect and angiogenesis. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	15
78	The Underlying Biology and Therapeutic Vulnerabilities of Leptomeningeal Metastases in Adult Solid Cancers. <i>Cancers</i> , 2021, 13, 732.	1.7	14
79	The ShcA PTB Domain Functions as a Biological Sensor of Phosphotyrosine Signaling during Breast Cancer Progression. <i>Cancer Research</i> , 2013, 73, 4521-4532.	0.4	13
80	DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy. <i>Anti-Cancer Drugs</i> , 2018, 29, 774-785.	0.7	12
81	The Tyrosine Kinome Dictates Breast Cancer Heterogeneity and Therapeutic Responsiveness. <i>Journal of Cellular Biochemistry</i> , 2016, 117, 1971-1990.	1.2	11
82	p66ShcA functions as a contextual promoter of breast cancer metastasis. <i>Breast Cancer Research</i> , 2020, 22, 7.	2.2	10
83	The SHCA adapter protein cooperates with lipoma-preferred partner in the regulation of adhesion dynamics and invadopodia formation. <i>Journal of Biological Chemistry</i> , 2020, 295, 10535-10559.	1.6	10
84	Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy. <i>Cell Reports</i> , 2022, 39, 110634.	2.9	10
85	Future directions for bone metastasis research “ highlights from the 2015 bone and the Oncologist new updates conference (BONUS). <i>Journal of Bone Oncology</i> , 2016, 5, 57-62.	1.0	9
86	Intra-tumor delivery of zoledronate mitigates metastasis-induced osteolysis superior to systemic administration. <i>Journal of Bone Oncology</i> , 2017, 6, 8-15.	1.0	9
87	CCN3/Nephroblastoma Overexpressed Is a Functional Mediator of Prostate Cancer Bone Metastasis That Is Associated with Poor Patient Prognosis. <i>American Journal of Pathology</i> , 2019, 189, 1451-1461.	1.9	9
88	Afadin (AF6) in cancer progression: A multidomain scaffold protein with complex and contradictory roles. <i>BioEssays</i> , 2021, 43, e2000221.	1.2	9
89	HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin. <i>Oncogene</i> , 2022, 41, 1701-1717.	2.6	8
90	GPNMB methylation: a new marker of potentially carcinogenic colon lesions. <i>BMC Cancer</i> , 2018, 18, 1068.	1.1	5

#	ARTICLE	IF	CITATIONS
91	A phase I/II study of CR011-vcMMAE, an antibody-drug conjugate, in patients (pts) with locally advanced or metastatic breast cancer (MBC). <i>Journal of Clinical Oncology</i> , 2009, 27, 1067-1067.	0.8	3
92	Expanding the armamentarium for neutrophil-mediated angiogenesis. <i>Hepatology</i> , 2017, 65, 1796-1798.	3.6	1
93	Abstract B056: Non-V600 BRAF mutations in melanoma: actionable targets for rational drug combinations., 2018, , .		1
94	Featuring the guest editors: Special issue tumor microenvironment. <i>Cancer Letters</i> , 2016, 380, 201-202.	3.2	0